Amgen (AMGN) Offering Possible 20.19% Return Over the Next 22 Calendar Days

[view original post]

Amgen’s most recent trend suggests a bearish bias. One trading opportunity on Amgen is a Bear Call Spread using a strike $207.50 short call and a strike $212.50 long call offers a potential 20.19% return on risk over the next 22 calendar days. Maximum profit would be generated if the Bear Call Spread were to expire worthless, which would occur if the stock were below $207.50 by expiration. The full premium credit of $0.84 would be kept by the premium seller. The risk of $4.16 would be incurred if the stock rose above the $212.50 long call strike price.

The 5-day moving average is moving down which suggests that the short-term momentum for Amgen is bearish and the probability of a decline in share price is higher if the stock starts trending.

The 20-day moving average is moving down which suggests that the medium-term momentum for Amgen is bearish.

The RSI indicator is at 23.7 level which suggests that the stock is neither overbought nor oversold at this time.

To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here


LATEST NEWS for Amgen

2 Dividend Stocks to Buy Right Now
Fri, 19 Nov 2021 16:00:00 +0000
Second, dividend stocks have historically outperformed their peers that do not pay dividends. Two companies that would be great additions to your dividend portfolio are pharma giants Bristol Myers Squibb (NYSE: BMY) and Amgen (NASDAQ: AMGN). The company continues to post solid financial results thanks to its rich lineup of drugs.

Amgen Awards The Bath Institute of Rheumatic Diseases $25,000 Through UPLIFT Innovation Challenge
Wed, 17 Nov 2021 14:00:00 +0000
Amgen (NASDAQ:AMGN) today announced the awarding of a one-time $25,000 grant to the Bath Institute of Rheumatic Diseases (BIRD) as part of the Understanding Psoriatic Disease Leveraging Insights for Treatment (UPLIFT) Innovation Challenge. In partnership with the International Federation of Psoriasis Associations (IFPA), the UPLIFT Innovation Challenge aims to make an impact within the psoriatic disease community by fostering the development of actionable solutions to address a challenge that pe

The Zacks Analyst Blog Highlights: Disney, Amgen, Booking Holdings, General Motors, and BCE
Tue, 16 Nov 2021 18:07:06 +0000
The Zacks Analyst Blog Highlights: Disney, Amgen, Booking Holdings, General Motors, and BCE

Top Analyst Reports for Disney, Amgen & Booking.com
Mon, 15 Nov 2021 19:20:07 +0000
Today’s Research Daily features new research reports on 16 major stocks, including The Walt Disney Company (DIS), Amgen Inc. (AMGN), and Booking Holdings Inc. (BKNG).

Amgen’s (AMGN) KRAS Inhibitor Gets CHMP Nod for Lung Cancer
Mon, 15 Nov 2021 16:20:04 +0000
The CHMP gives a positive opinion on, and recommends approval to Amgen’s (AMGN) KRAS inhibitor, Lumykras for the treatment of advanced non-small-cell lung cancer.

Be Sociable, Share!

Related Posts